- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SGEN
Recent news which mentions SGEN
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
February 27, 2023
From Benzinga
This is what Warren Buffett, a self-described ‘so-so investor,’ says is his ‘secret sauce’
February 27, 2023
From MarketWatch
Seagen, Occidental Petroleum And 3 Stocks To Watch Heading Into Monday
February 27, 2023
From Benzinga
From MarketWatch
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
February 26, 2023
From Benzinga
JMP Securities Maintains Market Outperform Rating for Seagen: Here's What You Need To Know
February 17, 2023
Tickers
SGEN
From Benzinga
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 16, 2023
From Benzinga
Analysts Are Bullish On Seagen's Catalyst-Rich Pipeline, Finding No Problem With No M&A
February 16, 2023
Tickers
SGEN
From Benzinga
KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday
February 16, 2023
From Benzinga
Pagaya Technologies To Rally Around Over 120%? Here Are 10 Other Analyst Forecasts For Thursday
February 16, 2023
From Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
February 14, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
February 06, 2023
From Benzinga
RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday
February 06, 2023
From Benzinga
RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday
February 06, 2023
From Benzinga
From Benzinga
From Benzinga
Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
January 20, 2023
From Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
December 25, 2022
From Benzinga
Why Seagen Stock Is Trading Higher During Monday's Session
December 12, 2022
Tickers
SGEN
From Benzinga
2 Growth Stocks to Buy if the Bear Market Continues in 2023
December 01, 2022
From Motley Fool
Cancer-Focused Imago BioSciences Shares Soar After Merck Deal
November 21, 2022
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.